| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, ... Nature 462 (7269), 108-112, 2009 | 3065 | 2009 |
| K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions JM Ostrem, U Peters, ML Sos, JA Wells, KM Shokat Nature 503 (7477), 548-551, 2013 | 2150 | 2013 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1461 | 2012 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 1007 | 2010 |
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR ML Sos, M Koker, BA Weir, S Heynck, R Rabinovsky, T Zander, ... Cancer research 69 (8), 3256-3261, 2009 | 652 | 2009 |
| Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling J Chmielecki, J Foo, GR Oxnard, K Hutchinson, K Ohashi, R Somwar, ... Science translational medicine 3 (90), 90ra59-90ra59, 2011 | 589 | 2011 |
| Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 582 | 2011 |
| MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition G Mollaoglu, MR Guthrie, S Böhm, J Brägelmann, I Can, PM Ballieu, ... Cancer cell 31 (2), 270-285, 2017 | 459 | 2017 |
| Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation HB Salvesen, SL Carter, M Mannelqvist, A Dutt, G Getz, IM Stefansson, ... Proceedings of the National Academy of Sciences 106 (12), 4834-4839, 2009 | 352 | 2009 |
| Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions ML Sos, K Michel, T Zander, J Weiss, P Frommolt, M Peifer, D Li, R Ullrich, ... The Journal of clinical investigation 119 (6), 1727-1740, 2009 | 323 | 2009 |
| Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants JM Heuckmann, H Balke-Want, F Malchers, M Peifer, ML Sos, M Koker, ... Clinical Cancer Research 18 (17), 4682-4690, 2012 | 301 | 2012 |
| Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, ... Proceedings of the National Academy of Sciences 106 (43), 18351-18356, 2009 | 296 | 2009 |
| A crucial requirement for Hedgehog signaling in small cell lung cancer KS Park, LG Martelotto, M Peifer, ML Sos, AN Karnezis, MR Mahjoub, ... Nature medicine 17 (11), 1504-1508, 2011 | 285 | 2011 |
| A neo-substrate that amplifies catalytic activity of parkinson’s-disease-related kinase PINK1 NT Hertz, A Berthet, ML Sos, KS Thorn, AL Burlingame, K Nakamura, ... Cell 154 (4), 737-747, 2013 | 267 | 2013 |
| Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen, AH Scheel, ... Clinical Cancer Research 22 (19), 4837-4847, 2016 | 257 | 2016 |
| Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation ML Sos, HB Rode, S Heynck, M Peifer, F Fischer, S Klüter, VG Pawar, ... Cancer research 70 (3), 868-874, 2010 | 243 | 2010 |
| ALK mutations conferring differential resistance to structurally diverse ALK inhibitors JM Heuckmann, M Hölzel, ML Sos, S Heynck, H Balke-Want, M Koker, ... Clinical Cancer Research 17 (23), 7394-7401, 2011 | 230 | 2011 |
| K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways M Scheffler, MA Ihle, R Hein, S Merkelbach-Bruse, AH Scheel, ... Journal of Thoracic Oncology 14 (4), 606-616, 2019 | 205 | 2019 |
| A framework for identification of actionable cancer genome dependencies in small cell lung cancer ML Sos, F Dietlein, M Peifer, J Schöttle, H Balke-Want, C Müller, M Koker, ... Proceedings of the National Academy of Sciences 109 (42), 17034-17039, 2012 | 191 | 2012 |
| Squamous cell lung cancer: from tumor genomics to cancer therapeutics DR Gandara, PS Hammerman, ML Sos, PN Lara Jr, FR Hirsch Clinical cancer research 21 (10), 2236-2243, 2015 | 180 | 2015 |
